CEL-SCI CORP (CVM) Stock Overview
USA - NYSEARCA:CVM - US1508377066 - Common Stock
CVM Key Statistics, Chart & Performance
The current stock price of CVM is 8.96 USD. In the past month the price increased by 2.35%. In the past year, price decreased by -66.37%.
CVM Latest News, Press Relases and Analysis
CVM Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 21.49 | 402.09B | ||
| AMGN | AMGEN INC | 13.27 | 155.77B | ||
| GILD | GILEAD SCIENCES INC | 15.5 | 148.84B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.88 | 108.05B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.75 | 61.65B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 62.85B | ||
| ARGX | ARGENX SE - ADR | 90.15 | 51.12B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5.09 | 34.61B | ||
| INSM | INSMED INC | N/A | 34.43B | ||
| NTRA | NATERA INC | N/A | 26.49B | ||
| BNTX | BIONTECH SE-ADR | N/A | 25.32B | ||
| BIIB | BIOGEN INC | 9.35 | 21.96B |
Related stock screener links
About CVM
Company Profile
CEL-SCI Corp. is a clinical-stage biotechnology company, which engages in the research, development, and manufacture of investigational immunotherapy products for the treatment of cancer and infectious diseases. The company is headquartered in Vienna, Virginia. The company is engaged in research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body’s natural defense system. The company is focused on the development of product candidates and technologies, including Multikine and Ligand Epitope Antigen Presentation System technology (LEAPS). Multikine (Leukocyte Interleukin, Injection), a true first-line cancer therapy, which is designed to help the immune system target the tumor at a time when the immune system is still relatively intact and thereby thought to be better able to mount an attack on the tumor. LEAPS is designed to stimulate the human immune system to more effectively fight bacterial, viral and parasitic infections as well as autoimmune conditions, allergies, transplantation rejection and cancer, when it cannot do so on its own. The LEAPS candidates include CEL-2000, CEL-4000 and DerG-PG275(Cit) (aka, CEL-5000).
Company Info
CEL-SCI CORP
Suite 802, 8229 Boone Blvd .
Vienna VIRGINIA 22182 US
CEO: Geert Kersten
Employees: 0
Phone: 17035069460
CEL-SCI CORP / CVM FAQ
Can you describe the business of CEL-SCI CORP?
CEL-SCI Corp. is a clinical-stage biotechnology company, which engages in the research, development, and manufacture of investigational immunotherapy products for the treatment of cancer and infectious diseases. The company is headquartered in Vienna, Virginia. The company is engaged in research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body’s natural defense system. The company is focused on the development of product candidates and technologies, including Multikine and Ligand Epitope Antigen Presentation System technology (LEAPS). Multikine (Leukocyte Interleukin, Injection), a true first-line cancer therapy, which is designed to help the immune system target the tumor at a time when the immune system is still relatively intact and thereby thought to be better able to mount an attack on the tumor. LEAPS is designed to stimulate the human immune system to more effectively fight bacterial, viral and parasitic infections as well as autoimmune conditions, allergies, transplantation rejection and cancer, when it cannot do so on its own. The LEAPS candidates include CEL-2000, CEL-4000 and DerG-PG275(Cit) (aka, CEL-5000).
Can you provide the latest stock price for CEL-SCI CORP?
The current stock price of CVM is 8.96 USD. The price decreased by -2.18% in the last trading session.
What is the dividend status of CEL-SCI CORP?
CVM does not pay a dividend.
What is the ChartMill rating of CEL-SCI CORP stock?
CVM has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
What is the GICS sector and industry of CVM stock?
CEL-SCI CORP (CVM) operates in the Health Care sector and the Biotechnology industry.
Can you provide the PE ratio for CVM stock?
CEL-SCI CORP (CVM) does not have a PE ratio as the earnings reported over the last twelve months were negative (-21.57).
What is the next earnings date for CVM stock?
CEL-SCI CORP (CVM) will report earnings on 2026-01-12, after the market close.
CVM Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to CVM. When comparing the yearly performance of all stocks, CVM is a bad performer in the overall market: 91.11% of all stocks are doing better.
CVM Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to CVM. CVM has a bad profitability rating. Also its financial health evaluation is rather negative.
CVM Financial Highlights
Over the last trailing twelve months CVM reported a non-GAAP Earnings per Share(EPS) of -21.57. The EPS increased by 42.99% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -125% | ||
| ROE | -361.85% | ||
| Debt/Equity | 0.89 |
CVM Forecast & Estimates
5 analysts have analysed CVM and the average price target is 306 USD. This implies a price increase of 3315.18% is expected in the next year compared to the current price of 8.96.